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Background: Our review of the scientific literature focused on an analysis of studies describing 
instances of methylphenidate treatment leading (or not) to behavioral changes in the pediatric, 
adolescent, and adult populations.
Materials and methods: We conducted a literature search in PubMed, Medline, and Google 
using the keywords “methylphenidate”, “behavioral changes”, “adverse effects”, and “side 
effects”. A total of 44 studies were identified as reporting on the effects and adverse effects of 
methylphenidate administration, and were included in the analysis.
Results: Five studies specifically set out to study, record, and discuss changes in behavior. 
Eight studies did not set out to study behavioral effects, but record and discuss them. A total 
of 28 studies recorded behavioral effects, but failed to discuss these further. Three studies did 
not include behavioral effects.
Conclusion: This review records what data have been published in respect of changes in 
behavior in association with the use of methylphenidate. While there is some evidence to sug-
gest that methylphenidate causes changes in behavior, the majority of the studies reviewed paid 
little or no attention to this issue. Based on the available data, it is impossible to determine the 
point at which such behavioral effects occur. The frequency of occurrence of behavioral effects 
is also impossible to determine with certainty. Based on the available data, it is not possible to 
rule out whether behavioral effects may persist or not persist once treatment is discontinued. In 
conclusion, despite countless publications and extensive administration, especially to children, 
we have insufficient data to judge the long-term effects and risks of methylphenidate taking.
Keywords: methylphenidate, changes in behavior, attention-deficit/hyperactivity disorder, 
children, adults, adverse effects
Introduction
Methylphenidate is used primarily in the treatment of children, adolescents, and adults 
with attention-deficit/hyperactivity disorder (ADHD). Furthermore, it is used in the 
treatment of narcolepsy, major depression disorder, and in patients with terminal cancer. 
Methylphenidate is usually prescribed for oral or transdermal use. As methylphenidate 
increases the ability to concentrate, it is sometimes used to enhance cognitive ability. In the 
treatment of ADHD, the aim of methylphenidate is to help to improve ADHD symptoms, 
such as difficulty paying attention or being hyperactive or impulsive. In 2012, Britton 
stated that until 2011, not a single study had been published on the long-term effects of 
treatment with methylphenidate.1 Since then, preclinical research has identified possible 
changes in brain structure and function, which suggest that “early pharmacotherapy can 
produce neuroadaptations that can persist long after drug treatment has ended”.1
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In rats, exposure to methylphenidate during preadoles-
cence has been shown to lead to behavioral changes, such as 
increased depressive symptoms, as well as a reduction in the 
ability to adapt to a familiar environment.2 Adult rats treated 
with methylphenidate during adolescence were shown to be 
less responsive to positive stimuli (such as a novel environ-
ment or sex) and more susceptible to stressful situations.3 
Bolaños et al stated that: 
[our] findings show that developmental administration 
of MPH [methylphenidate] results in aberrant behavioral 
adaptations during adulthood, and these results underscore 
the need for further developmental research geared toward 
a better understanding of the mechanisms underlying MPH-
induced behavioral plasticity.3
In a study of seven healthy adult humans, a dose of 0.25 mg/kg 
body weight or higher resulted in the inhibition of more than 
50% of dopamine transporters.4 Long-term treatment with 
methylphenidate in humans led to significantly increased 
activity in the caudate and putamen regions. Wang et al sug-
gested that the increased activity of dopamine transporters 
compensates for their pharmacological inhibition, resulting in 
increased inattention and the need for an increase in the dose 
administered.5 There are a plethora of studies investigating 
changes in brain structure and function, but the focus in this 
publication was on clinical studies.
In her review of studies investigating the neuropsy-
chological effects of methylphenidate, Advokat concluded 
that the use of stimulant drugs, such as methylphenidate or 
amphetamine, leads to increased attention and concentra-
tion, but does not result in improved learning or academic 
achievements. The author explained that her review of more 
than 30 years of research involving children, adolescents, and 
students failed to show evidence of the desired effects in any 
of these age-groups. The author expressed concerns regarding 
the administration of stimulant drugs, such as methylpheni-
date, as these may lead to reduced impulsiveness, which in 
turn could result in impaired performance in cognitive tasks 
requiring flexibility and adaptability.6
In November 2015, a Cochrane review was published 
with the aim of assessing the beneficial and harmful effects 
of methylphenidate for children and adolescents with ADHD. 
The authors stated:
At the moment, the quality of the available evidence means 
that we cannot say for sure whether taking methylphenidate 
will improve the lives of children and adolescents with 
ADHD.7
Changes in behavior can be defined as gradual yet per-
manent changes affecting the defining features of an indi-
vidual’s personality without causing significant impairment 
in intellectual ability.8 For this study, we included the follow-
ing symptoms as changes in behavior: abnormal behavior, 
accidental injury, agitation, aggression, anxiety, depression, 
depressed mood, disinterested in others, dizziness, drowsi-
ness, emotional lability, euphoria, feeling jittery, irritability, 
mood alteration, nail biting, nervousness, nightmares, prone 
to crying, psychomotor hyperactivity, restlessness, sadness, 
staring, talks less, and tics. Methylphenidate can cause 
cardiovascular, abdominal, psychiatric, growth and devel-
opment, and neurological side effects. For this study, the 
focus was on psychiatric symptoms. Methylphenidate targets 
the central nervous system by inhibiting the reuptake of 
dopamine.4,8–11 To a lesser extent, it also inhibits the reuptake 
of norepinephrine,9–11 and binds to the serotonin transporter, 
albeit with low affinity.9,11,12
Chemically speaking, methylphenidate belongs to the 
amphetamines.9 In 1981, it was included as part of the 
licensed prescription drugs listed in annex III of the newly 
amended German Narcotic Drugs Act (Betäubungsmit-
telgesetz). Amendments to the professional guidelines on 
the prescription of stimulant drugs (Arzneimittel-Richtline) 
made by the Federal Ministry of Health in 2010 meant that 
only “specialists in behavioral disorders of children and/or 
adolescents” would be allowed to prescribe stimulant drugs 
for use in the treatment of ADHD.13 Our review of the sci-
entific literature focused on an analysis of studies describing 
instances of methylphenidate treatment leading (or not) to 
behavioral changes.
Materials and methods
We conducted a literature search in PubMed, Medline, and 
Google using the keywords “methylphenidate”, “behavioral 
changes”, “adverse effects”, and “side effects”. A total of 
44 studies were identified as reporting on the effects and 
adverse effects of methylphenidate administration, and 
were included in the analysis. In some studies, the results 
were divided among several publications. The publication 
period for articles was from 1990 until 2015. We did our 
last search on July 9, 2015. We included studies focusing 
on methylphenidate. We included studies with more medi-
cines than methylphenidate if they were focusing on meth-
ylphenidate. We excluded studies with more medicines than 
methylphenidate if they were focusing on medicines other 
than methylphenidate. We excluded studies focusing only 
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Behavior changes during and after methylphenidate treatment
Long-term effects of the drug were one of the main issues 
under consideration during the selection of studies. However, 
the current body of literature contains only a small number of 
articles on the long-term effects of methylphenidate. There 
was significant variation among the 44 studies reviewed, 
some of which were blind, others open-label. Some of the 
comparison groups received a placebo, while others received 
a different drug product. Some studies compared different 
forms of methylphenidate, while others compared meth-
ylphenidate at different doses.
Comparison was rendered more difficult by some of the 
studies involving small numbers of participants and being 
of limited duration: 57% of the studies lasted for less than 
80 days, and patients in the shortest study14 received the drug 
for only 5 days. Despite its small size, Silva et al14 was judged 
to be of good quality, due to its randomized, double-blind, 
placebo-controlled, crossover trial design, and was included 
in the review.
Three of the studies had fewer than 30 participants. Bron 
et al,15 which involved 27 adult participants, was selected 
due to its good-quality study design, and the fact that partici-
pants had not previously been exposed to methylphenidate. 
Ghuman et al16 was selected due to the fact that it involved 
27 very young participants (aged 3–5 years), which meant 
that methylphenidate was used off-label. All of the partici-
pants were methylphenidate-naïve, and treatment duration 
was relatively long compared to the other studies, lasting 
between 3 and 24 months. The study did not receive any 
funding, and in contrast to the other studies reviewed, did 
not include participants with concomitant psychiatric disor-
ders. The smallest study selected was Maayan et al,17 which 
involved nine very young participants, all of whom were aged 
between 4 and 5 years and methylphenidate-naïve.
Some studies were included in the review despite the fact 
that they did not focus on side effects. One such example 
was Barbaresi et al,18 a retrospective cohort study, which 
followed participants from birth until the age of 17.2 years. 
While the authors described the long-term treatment with 
methylphenidate as effective, their conclusion was not based 
on the use of specific assessment tools. Assessment was by 
means of responses from participants and teachers, who 
were asked to rate the effect of treatment (positive effect, 
no effect, or not known). While the authors used their data 
to argue that long-term treatment with stimulant drugs had a 
positive effect, their data should be regarded as of question-
able quality. Not only is it impossible to check whether the 
medication was administered at all, but questions regarding 
the effectiveness of treatment were too generic, and both 
students and teachers may have been overly positive in 
their responses.
Smith et al,19 who failed to provide any information on side 
effects, included results from as early as 1989. A longitudinal 
study conducted over 14 years, it is nonetheless worthy of 
mention, not only due to its sheer length but also because 
it showed no difference between participants receiving the 
drug and a comparison group from the general population. 
Analysis and discussion of results were modeled on Aagaard 
and Hansen.20 While the article by Aagaard and Hansen also 
included data on amphetamine, atomoxetine, and modafinil, 
we did not include any studies focusing on these medicines. 
The review by Aagaard and Hansen was published in 2011. 
From this paper, we included 14 studies in our review: 
Biederman et al,21 Arabgol et al,22 Maayan et al,17 Amiri 
et al,23 Findling et al,24 Newcorn et al,25 Greenhill et al,26 
Gau et al,27 Silva et al,14 Kemner et al,28 Swanson et al,29 and 
Kratochvil et al.30 We identified and included an additional 
29 studies: eleven of these included adult participants only, 
or participants between 4 and 65 years of age. Another ten, 
which involved children and adolescents, were published 
between 2011 and 2015. We also included an additional 
nine studies that had been published in 2010 or earlier. An 
overview of the studies is listed in Table 1.





Age (years) Focus on 
side effects
Withdrawal (%)
Adler et al51 5 weeks + 
6 months
None 218 (5 weeks),  
170 (6 months)
18–60 Yes 19.7
Adler et al31 6–12 months None 550 18–65 Yes 18.5
Bejerot et al52 2 years None 133 31.1±10.9 No 17
Bron et al15 6 weeks None 27 18–55 No 11.1
Buitelaar et al32 12 weeks None 401, 370 (OL) 18–63 Yes 4.3, 5 (OL)
Buitelaar et al65 56 weeks None 155 (OL), 45 (wd) 18–65 Yes 10.4 (OL)
Casas et al33 14 weeks 1 week 279 18–65 No 16.9 (G1), 20.7 (G2), 1 (P)
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Studies included in the analysis differed in terms of study 
design, and included randomized parallel-group studies with 
a placebo arm (13),21–26,31–44 randomized crossover studies 
(ten),14,15,29,36,45–50 open-label studies (17),17,19,27,28,30,32,51–61 and 
retrospective studies (four).16,18,62,63
inclusion criteria
Thirteen of the studies required participants to be 
methylphenidate-naïve.15–17,19,23,40–42,44,45,47,53,59,60,64 In 19 of 
the studies, methylphenidate was discontinued between 1 and 
30 days prior to the start of the study.14,22,24,25,28–33,44,48–51,61,65,66 
Seven of the studies did not specify whether participants had 
had previous exposure to methylphenidate.18,27,34–39,46,52,57,62,63 
Six of the studies included both methylphenidate-naïve 
participants and participants with prior exposure to methyl-
phenidate.21,26,54–56,58
Funding arrangements
Nineteen of the studies were funded by pharmaceutical 
companies.18,21,24,25,27–29,31–33,44,49,51,54,56,58,61,65,66 Ten were funded 
using government or university funding.19,23,34–39,43,45,47,48,50,52,64 






Age (years) Focus on 
side effects
Withdrawal (%)
Huss et al54,55 66 weeks None 725 18–60 Yes 11.3 (P1), 3.8 (P2), 5 (P3), 2.7 (eS)
Kooij et al45 7 weeks None 45 20–56 No 0
valdizán-Usón et al62 1 year None 730 4–65 No NK
Amiri et al23 6 weeks None 60 6–15 No 0
Arabgol et al22 6 weeks None 33 6.5–16 No 6.23
Barbaresi et al18 33.8 months 17.2 years 283 9.8 mean age No NK
Barkley et al46 30 days None 83 5–13 Yes 3.6
Biederman et al21 19 weeks None 161 6–14 No 4.35
Cherland and Fitzpatrick63 21 months None 98 4–17 Yes NK
Döpfner et al56 6–12 weeks None 822 7–16 No 3.16
efron et al47 4 weeks None 125 104.8 months, 
mean age
Yes 3.2
Findling et al24 3 weeks None 318 6–12 No 6.6
Garg et al57 8 weeks None 69 (33 MPH) 6–14 Yes 18.18
Gau et al27 28 days None 64 6–15 No 0
Ghuman et al16 24 months None 27 3–5 No 6
Greenhill et al26 9 weeks None 97 6–17 No 0
Haertling et al58 12 weeks None 262 10.9±2.5 No NK
Karabekiroglu et al59 15 days None 90 5–16 Yes 8.9
Kemner et al28 21 days None 1,323 (850 MPH) 6–12 No 4.8
Khajehpiri et al60 6 months None 71 4–15 Yes 0
Kratochvil et al30 10 weeks None 228 (44 MPH) 7–15 months, 
7–9 weeks
No 11.4
Lee et al48 2 weeks None 157 6–12 Yes NK
Maayan et al17 4 weeks None 11 4–5 No 27
MTA group34–39 14 months 24 months,  
6 and 8 years
579 7–9.9 No ,1
Newcorn et al25 12 weeks 6 weeks 516 6–16 No 5
PATS group40–42 70 weeks 3, 4, and 
6 years
165 3–5.5 Yes 11
Pelham et al49 3 weeks None 70 6–12 No 0
Smith et al19 14 years Longitudinal 131 1–17 No NK
Ramtvedt et al64 6 weeks None 34 11.3 mean age Yes 2.94
Robb et al61 6–8 weeks None 45 6–12 Yes 13.3
Silva et al14 2 weeks None 54 6–12 No 1 (P)
Steele et al66 8 weeks None 145 6–12 No 11.6
Stein et al50 4 weeks None 47 5–16 Yes NK
Swanson et al29 21 days None 184 6–12 No 0
wigal et al44 12 weeks 30 days 230 6–18 No 2
Zarinara et al43 6 weeks None 38 6–13 No 5.3
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Behavior changes during and after methylphenidate treatment
Five were not in receipt of funding,16,22,53,57,62 while six failed to 
provide information on funding arrangements.14,30,46,59,60,63
Comparison group
In 21 of the studies, the comparison group received a 
placebo.14,15,21,24–26,29,32,33,40–42,44–46,48–51,54,61,64,65 One of the 
studies compared methylphenidate with modafinil,23 four 
of the studies compared it with atomoxetine,25,28,30,57 one 
with reboxetine,22 three with dexamphetamine,47,52,64 and 
one with venlafaxine.43 Five of the studies compared 
different forms of methylphenidate,24,27,29,49,66 while four 
compared methylphenidate at different doses.33,40–42,46,50 
Ten of the studies did not include a comparison 
group.16–18,31,53,56,58–60,62
Study duration
Seven of the studies were conducted over a period of 
between 11 and 21 days,14,24,28,29,48,49,59 five lasted for 
between 22 and 40 days,17,27,46,47,50 12 lasted for between 
41 and 80 days,15,22,23,26,30,43,45,56,57,61,64,66 and 20 for more than 
80 days.16,18,19,21,25,31–42,44,51–54,58,60,62,63,65
Study population
In ten of the studies, participants were adults aged between 
18 and 65 years.15,31–33,45,51–55,65 Of the 2,783 participants 
included in these studies, 1,498 were males. In 33 of the 
studies, participants were aged between 3 and 17 years. 
Of the 6,620 included in these studies, 3,678 were males. 
Three of the studies did not provide any information on sex 
distribution among participants.34–39,48,63 In one of the stud-
ies, 590 of the 730 participants aged between 4 and 65 years 
were males.62
Size of studies
Three of the studies had fewer than 30 participants,15–17 
16 had between 31 and 100 participants,14,22,23,26,27,43,45,46,49,50, 
57,59,60,61,63,64 18 between 101 and 500 participants,18,19,21,24,29,30, 
32,33,40–42,44,47,48,51–53,58,65,66 while seven had more than 500 partici-
pants.25,28,31,34–39,54,56,62
Rates of withdrawal due to side effects
Among the studies reviewed, withdrawal rates due to side 
effects were found to be between 0 and 27%. Eight of the 
studies had a zero withdrawal rate14,23,26,27,29,45,49,60 (one of these 
recorded an early withdrawal by one participant allocated 
to the placebo group).14 Seven of the studies did not pro-
vide information on either the number of withdrawals or 
withdrawal rate due to side effects.18,19,48,50,58,62,63
Classification of side effects
Of the studies, 27 did not provide information on the methods 
or definitions employed in the reporting of side effects. In one 
of the studies, side effects were reported if experienced by 
at least 1% of participants,28 in four studies the cutoff was at 
least 2% of participants,26,29,32,49 in one study at least 3% of 
participants,24 in seven studies at least 5%,25,30,33,44,54,55,61,65 and 
in two studies at least 10%.31,66 Two of the studies recorded 
the most commonly observed side effects only.51,40–42
Frequency of side effects
Frequency of side effects varied enormously between 
studies. In Haertling et al, 13.7% of participants reported 
experiencing side effects.58 In Khajehpiri et al, the 
figure was 100%.60 Sixteen studies failed to provide this 
infor ma tion.17,19,23,27,29,30,40–44,47,49,50,59,63
Behavioral changes
Side effects associated with changes in behavior are listed 
in Table 2. Five studies specifically addressed the issue 
of behavioral changes, and duly recorded and described 
these.40–42,51,59,63,64 Cherland and Fitzpatrick focused on the 
psychotic side effects of methylphenidate.63 The other studies 
addressed behavioral changes in relation to the long-term safety 
of methylphenidate,51 its short-term side effects,63 its safety and 
tolerability,40–42 and its use in minimizing adverse events.64
The most frequently recorded symptoms were “irritabil-
ity” (0%–80%), “prone to crying” (1%–71%), “staring” 
(21%–62%), “anxiety” (2%–61%), “sadness” (0%–56%), 
“nail biting” (22%–45%), “euphoria” (16%–43%), and “talks 
less” (27%–42%). Among studies with adult participants, 
the most commonly recorded symptoms were “drowsiness” 
(0%–32%) and “nervousness” (3%–23%).
Table 2 does not include individual cases of severe 
side effects. Casas et al33 and Huss et al54,55 mentioned one 
attempted suicide each. Fredriksen et al53 explained that the 
suicidal thoughts reported by one of the participants in their 
study were classed as not drug-induced, as they occurred 
several months after methylphenidate had been discontinued. 
Adler et al31 listed side effects reported by more than 10% of 
participants; 1.8% of their participants were reported as expe-
riencing psychiatric symptoms, such as mania, aggression, 
and paranoia. Bejerot et al52 reported that three of their par-
ticipants with concomitant psychiatric disorders developed 
such symptoms as hallucinations, agitation, and aggression, 
or seizures. Kemner et al28 reported that participants treated 
with methylphenidate developed severe side effects, such 
as mania, paranoia, crying/fear/aggression, and kicking the 
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Table 2 Overview of behavioral changes observed in persons treated with methylphenidate






Agitation Aggression Anxiety Depression Depressed 
mood
Adler et al51 *1) – – 5% – 12% – –
Adler et al31 10 – – – – 13% – –
Bejerot et al52 – – – – – – – –
Bron et al15 – – – – – – – –
Buitelaar et al32 2 – – – – 5% – 4%
Buitelaar et al65 4–5 *2) – – – – 2% – 5%
Casas et al33 5 – – 8% – 9% – 6%
Fredriksen et al53 – – – Yes Yes Yes – –
Huss et al54,55 5 – – – – 5% – –
Kooij et al45 – – – – – – – –
valdizán-Usón et al62 – – – – – – – –
Amiri et al23 – – – – – 13% – –
Arabgol et al22 – – – – – – – –
Barbaresi et al18 – – – – – – – –
Barkley et al46 – – – – – 58% – –
Biederman et al21 – – – – – Yes – –
Cherland and 
Fitzpatrick63
– – – – – – – –
Döpfner et al56 – – – – 3% – 1% 1%
efron et al47 – – – – – 61% – –
Findling et al24 3 3% – – 3% – – –
Garg et al57 – – – – – – – –
Gau et al27 – – – – – 31% – –
Ghuman et al16 – – – 11% – 3% – –
Greenhill et al26 2 – – – – – – –
Haertling et al58 – – – 1% 1% – 1% –
Karabekiroglu et al59 – – – – – – – –
Kemner et al28 1 1% – – 1% – – –
Khajehpiri et al60 – – – 36% – – – –
Kratochvil et al30 5 5% 12% – – – 5% –
Lee et al48 – – – – – 38% – –
Maayan et al17 – – – – 9% – – –
MTA group34–39 – – – – – – – –
Newcorn et al25 5 – – – – – – –
PATS group40–42 *3) – – – 4% 3% – –
Pelham et al49 2 – 4% – – – – –
Smith et al19 – – – – – – – –
Ramtvedt et al64 – – – – – 30% – –
Robb et al61 5 – – – 6% – – –
Silva et al14 – – – – – – – –
Steele et al66 10 – – 11% – – – –
Stein et al50 – – – – – 55% – –
Swanson et al29 2 – – – – – – –
wigal et al44 5 – – – – – – –
Zarinara et al43 – – – – – – – –
Total – 1%–5% 4%–12% 1%–36% 1%–9% 2%–61% 1%–5% 1%–6%
Placebo in total – 0%–4% 0%–3% 0%–1% 0%–5% 1%–58% – 1%–5%
Adult – – – 5%–8% – 2%–13% – 4%–6%
Placebo adult – – – 1% – 1%–7% – 1%–5%
Child – 1%–5% 4%–12% 1%–36% 1%–9% 3%–61% 1%–5% 1%
Placebo child – 0%–4% 0%–3% – 0%–5% 1%–58% – –
Study Disinterested 
in others








Adler et al51 – – – – – 13% 8% – –
Adler et al31 – – – – – – 10% – –
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Bron et al15 – – – – – – – – –
Buitelaar et al32 – 8% – – – – 5% – –
Buitelaar et al65 – – – – – – 4% – –
Casas et al33 – 12% – – – – 5% – –
Fredriksen et al53 – – – Yes – – – – –
Huss et al54,55 – 6% – – – – 6% – –
Kooij et al45 – 16% – – – 15% – –
valdizán-Usón et al62 – – – – – – – – –
Amiri et al23 – – – – – – 20% – –
Arabgol et al22 – – 0 – – – 6% – –
Barbaresi et al18 – – – – – – – – –
Barkley et al46 43% 10% 25% – 43% – 66% – 29%
Biederman et al21 – – Yes Yes – – – – –
Cherland and 
Fitzpatrick63
– – – – – – – – –
Döpfner et al56 – – – – – – – – –
efron et al47 31% 12% 18% – 28% – 80% – 45%
Findling et al24 – – – 3% – – 3% – –
Garg et al57 – – 3% – – – 6% – –
Gau et al27 40% – 25% – 28% – 21% – 25%
Ghuman et al16 – – 18% 29% – – 29% – –
Greenhill et al26 – – – 3% – – 3% – –
Haertling et al58 – 1% – 1% – – – 1% –
Karabekiroglu et al59 – – – – – – – – –
Kemner et al28 – 1% – 1% – – 1% 1% –
Khajehpiri et al60 – – – – – – 57% – –
Kratochvil et al30 – – 0 5% – – – – –
Lee et al48 17% 6% 16% – 25% – 64% – 30%
Maayan et al17 – – 9% 18% – – – – –
MTA group34–39 – – – – – – – – –
Newcorn et al25 – – – – – – 6% – –
PATS group40–42 – – Yes 15% – – 8% 7% –
Pelham et al49 – 3% – – – – – – –
Smith et al19 – – – – – – – – –
Ramtvedt et al64 21% 18% 32% – 18% – 65% – –
Robb et al61 – 6% – 26% – – 13% – –
Silva et al14 – – – – – – 0 – –
Steele et al66 – – – 13% – – – – –
Stein et al50 34% 11% 28% – 16% – 71% – 22%
Swanson et al29 – – – – – – 1% – –
wigal et al44 – 9% – – – – – – –
Zarinara et al43 – – – – – – – – –
Total 17%–41% 1%–18% 0%–32% 1%–29% 16%–43% 13% 0%–80% 1%–10% 22%–45%
Placebo in total 17%–36% 0%–15% 8%–53% 0%–11% 25%–45% 2% 1%–80% 6% 15%–29%
Adult – 6%–17% 0%–32% – – 13% 4%–15% 10% –
Placebo, adult – 2%–7% 8%–53% – – 2% 1%–23% – –
Child 17%–41% 1%–18% 0%–32% 1%–29% 16%–43% – 0%–80% 1%–7% 22%–45%
Placebo, child 17%–36% 0%–15% 8%–53% 0%–11% 25%–45% – 1%–80% 6% 15%–29%




Restlessness Sadness Staring Talks less Tics
Adler et al51 – – – 5% – – – – –
Adler et al31 – – – – – – – – –
Bejerot et al52 12% – – – – – – – 1%
Bron et al15 23% – – – – – – – –
Buitelaar et al32 3% – – – 5% – – – –
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Restlessness Sadness Staring Talks less Tics
Casas et al33 – – – – 9% – – – –
Fredriksen et al53 – – – – – – – – Yes
Huss et al54,55 – – – – 4% – – – –
Kooij et al45 – – – – – – – – 7%
valdizán-Usón et al62 – – – – – – – – –
Amiri et al23 – – – – – 20% – – –
Arabgol et al22 – – – – – – – – –
Barbaresi et al18 – – – – – – – – –
Barkley et al46 – 21% 59% 28% – 48% 57% 42% –
Biederman et al21 – – – – – – – – –
Cherland and 
Fitzpatrick63
– – – – – – – – –
Döpfner et al56 – – – – – 17% – – 12%
efron et al47 – 21% 71% – – 56% 62% 28% 28%
Findling et al24 – – – – – – – – 0
Garg et al57 – – – – – – – – –
Gau et al27 – 25% 47% – – – 31% 31% 18%
Ghuman et al16 – – 29% 3% – – – – –
Greenhill et al26 – – – – – – – – –
Haertling et al58 – – – – – – – – –
Karabekiroglu et al59 – – – – – – – – –
Kemner et al28 – – 1% – – – – – –
Khajehpiri et al60 – 24% – – – – – – 35%
Kratochvil et al30 10% – – – – – – – –
Lee et al48 – 13% 49% – – 38% 35% 27% 17%
Maayan et al17 – – – – – – – – –
MTA group34–39 – – – – – – – – –
Newcorn et al25 – – – – – – – – –
PATS group40–42 – – – – – – – – –
Pelham et al49 – – – 5% – – – – –
Smith et al19 – – – – – – – – –
Ramtvedt et al64 – 9% 65% – – 41% 21% 29% 15%
Robb et al61 – – – – – – – – –
Silva et al14 – – – – – – – – –
Steele et al66 – 13% – – – – – – –
Stein et al50 – 17% 54% – – 47% 54% 32% 17%
Swanson et al29 – – – – – – – – –
wigal et al44 – – – – – – – – –
Zarinara et al43 – – – – 26% – – – –
Total 3%–23% 9%–25% 1%–71% 3%–28% 4%–26% 0%–56% 21%–62% 27%–42% 0%–35%
Placebo in total 1% 12%–20% 38%–49% 0%–7% 0%–4% 31%–50% 30%–68% 15%–38% 2%–30%
Adult 3%–23% – – 5% 4%–9% – – – 1%
Placebo, adult 1% – – 7% 0%–4% – – – 2%
Child 10% 9%–25% 1%–71% 3%–28% 26% 0%–47% 21%–62% 27%–42% 0%–35%
Placebo, child – 12%–20% 38%–49% – – 31%–50% 30%–68% 15%–38% 4%–30%
Notes: *1) “most frequently recorded”. *2) 5 (recorded in open-label), 4 (recorded in withdrawal); *3) 15 most frequently recorded adverse events.
Three studies mentioned when the symptoms started. 
Adler et al51 reported that most of the symptoms occurred 
within the first month of therapy. In Adler et al,31 82.4% of 
symptoms were reported during the first 30 days. Arabgol 
et al reported that the symptoms occurred 1–2 weeks after 
the medication was started.22 None of the studies provided 
information on when the side effects started exactly, except 
Robb et al, who reported two severe side effects: one at 18 
days, and one at 9 days.61 Biederman et al stated that the 
same side effects were reported in treatment and in placebo 
washout.21 Three studies failed to offer any information about 
the time the symptoms occurred.19,24,34–39
Are the reported side effects reversible?
Most of the studies failed to provide information on whether 
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Behavior changes during and after methylphenidate treatment
In seven of the studies, patients were followed up after the 
end of the medication.18,19,25,33–42 However, none of these 
allowed conclusions to be drawn regarding the reversibility 
of reported side. Cherland and Fitzpatrick were vague in this 
respect, stating simply that “most” participants improved fol-
lowing withdrawal of the medication.63 Adler et al describes 
the symptoms experienced by some of the participants as 
reversible.31 In three of the studies, all reported side effects 
disappeared following withdrawal of the medication.17,46,47 
Two of the studies report that the side effects persisted until 
the end of the study.56,58
Discussion
Study design and selection of studies
Does methylphenidate cause changes in behavior? Current 
prescribing practices mean that many patients start taking 
methylphenidate as children and continue treatment until 
they reach adulthood. Five of the studies selected specifi-
cally recorded and discussed changes in behavior.31,40–42,59,63,64 
Unfortunately, these studies cannot be compared in terms of 
quality (Table 3).
Rates of withdrawal due to side effects
In 29 of the studies, participants withdrew early because of 
side effects. Withdrawal rates ranged from 0 to 27%, and 
six of the studies failed to provide this information at all. 
Three of the studies27,29,49 – two with a partial focus on the 
safety of methylphenidate27,29 – stipulated that participants 
had to be receiving a stable dose of methylphenidate prior 
to entry into the study. All three reported zero withdrawal 
rates. Inclusion criteria for 13 of the studies stipulated that 
participants had to be methylphenidate-naïve. Three of 
these23,45,60 reported zero withdrawal rates, while one19 failed 
to report this information. Maayan et al recorded the highest 
withdrawal rate – 27%.17 However, the study’s eleven partici-
pants did not constitute a representative sample. For studies 
that included only methylphenidate-naïve participants, the 
mean withdrawal rate was 6.7%. Studies that included only 
participants able to tolerate methylphenidate or that did not 
establish whether participants had prior exposure to the drug 
recorded a mean withdrawal rate of 7.4%. The reviewed 
data would thus suggest that there is no link between prior 
exposure to methylphenidate and early withdrawal due to 
side effects.
Changes in behavior
The occurrence of recorded changes in behavior differ 
widely. The symptom “irritability” was recorded by no 
subjects14 to 80% of subjects.47 In every case of the most 
frequently recorded symptoms, Efron et al recorded the 
highest percentages: “prone to crying” (71%), “staring” 
(62%), “anxiety” (61%), “sadness” (56%), “nail biting” 
(45%), “euphoria” (43%), and “talks less” (42%).47
Occurrence of side effects
While Khajehpiri et al reported side effects for all their 
participants,60 Haertling et al reported the lowest rate 
of occurrence of side effects (13.7%).58 Studies with 
methylphenidate-naïve participants reported side effects in 
67.7% of participants. Studies that did not require participants 
to be methylphenidate-naïve or required them to be able to 
tolerate methylphenidate recorded a side effect rate of 57.7%. 
What was the reason for the low rate of occurrence reported 
in Haertling et al?58 The study was similar to the other studies 
Table 3 Studies that recorded and discussed changes in behavior




PATS group40–42 Ramtvedt et al64
Study design Open-label Retrospective Open-label Crossover, parallel Crossover
Treatment period 6–12 months 21 months 15 days 70 weeks 6 weeks
Follow-up No No No Yes No
Patients completed 550 98 90 165 34
Age, years 18–65 4–17 5–15 3.5–5 11.3
Placebo group No No No Yes Yes
Methylphenidate-naïve No Not known Yes Yes Yes
Limit for symptoms 10% Not known Not known 15 most frequent Not known
Changes in behavior 1.8% Single cases No Yes Yes
Focus of study Changes in behavior in 
relation to long-term 
safety of methylphenidate
Psychotic 
side effects of 
methylphenidate
Short-term 





Use of methylphenidate 
in minimizing adverse 
events
Notes: For Adler et al, changes in behavior were mentioned in the article, but are not shown in the tables.31 For Cherland and Fitzpatrick, it was impossible to determine 
with certainty whether the behavioral changes observed were reversible.63 The Karabekiroglu et al study was specifically designed to study short-term effects.59 Subjects in 
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in terms of age distribution and number of participants. 
Nineteen percent of participants received methylphenidate 
for the first time. The remaining participants were already 
using methylphenidate, but in a different form. The study 
was funded by the pharmaceutical industry. If both the com-
parability of studies and the evaluation of side effects are to 
be improved, future studies will need to exclude participants 
with prior exposure to methylphenidate.
Barkley et al posited that any behavioral changes 
observed during their study had to be linked to the condi-
tion under study.46 They supported this assertion by stating 
that the same symptoms occurred during initial testing and 
during the placebo phase of the trial, and that the physi-
ological effects of methylphenidate disappeared within 24 
hours of administration. The authors’ assertion should be 
treated with caution. Participants were aged between 5 and 
13 years. Inclusion criteria stipulated that participants had to 
have developed ADHD symptoms before the age of 7 years. 
While no such information was provided in the article, it must 
be assumed that some of the participants would have been 
receiving drug-based treatment for a number of years prior to 
enrollment. The assertion that side effects cease completely 
24 hours after administration directly contradicts results 
from animal studies, which suggest that exposure leads to 
structural changes inside the brain, as well as clear changes 
in behaviors displayed by adult rats.2,3
Study funding and its impact on results
Some of the articles mentioned relevant results, but failed 
to discuss these further. Adler et al mentioned specifically 
instructing participants to report psychotic side effects, and 
that participants reported mania, aggression, and paranoia.51 
However, during their presentation of results, the authors 
introduced the rule that only “symptoms occurring in at least 
10% of participants” were to be classed as side effects. As 
psychiatric side effects only occurred in 1.8% of participants, 
these were not discussed any further. The study was con-
ducted in conjunction with the pharmaceutical industry. The 
study’s first author declared a conflict of interest. Casas et al 
reported that one participant attempted to commit suicide, 
but failed to provide any further details.33 It is impossible to 
establish whether side effects occurred during the washout 
period. The authors merely observed that no more than three 
participants from each arm of the study reported any side 
effects in the week between outcome measurements and 
follow-up visit. This rather vague statement leaves room 
for speculation. The study was funded by the pharmaceuti-
cal industry.
Are the reported side effects reversible?
Are reported side effects reversible once administration 
is discontinued? Only a few of the details provided in the 
studies can be verified. Even studies aimed at testing the 
safety of methylphenidate did not provide information on 
the cessation of side effects. Both Döpfner et al and Haertling 
et al reported side effects as not reversible until the end of the 
study.56,58 Only Barkley et al and Efron et al provided clear 
information in support of the statement that side effects were 
completely reversible.46,47 The other studies failed to provide 
information on this issue.
Lack of data
With the exception of the studies mentioned earlier, none 
of the studies discussed the issue of behavioral change. 
While many of the articles listed instances of behavioral 
change, the tables provided only listed side effects reported 
by a certain percentage of respondents (up to 10%). This 
of course raises the question of how many examples of 
behavioral change remain undetected among studies that 
only list side effects above a certain minimum frequency. 
Whether behavioral side effects are particularly common is 
of no real relevance. The fact that there is a real risk of such 
side effects developing should be reason enough to instill a 
sense of caution when prescribing methylphenidate. What 
is more, data from the reviewed studies do not rule out the 
possibility that the observed side effects may be irrevers-
ible. The MTA study may be able to provide some indirect 
answers.34–39 When compared with children from the control 
group, children enrolled in the MTA study were ten times 
more likely to be admitted to psychiatric institutions.
Future studies
With the exception of Cherland and Fitzpatrick, which was 
retrospective in design, none of the studies set out specifically 
and exclusively to study changes in behavior.63 What is more, 
most of the studies were too short to allow inferences to be 
made regarding the drug’s long-term effects. As the major-
ity of the studies did not include follow-up examinations, it 
is impossible to determine whether behavioral symptoms 
were reversible.
It would therefore be desirable if future studies were to 
meet the required quality criteria as determined by study 
design (multicenter, randomized, double-blind, placebo-
controlled), and if they were designed to ensure a study 
duration long enough to permit the study of long-term effects. 
It would also be desirable if future studies were to include a 
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Behavior changes during and after methylphenidate treatment
regarding the reversibility or irreversibility of behavioral 
effects. In terms of inclusion criteria, it would be desirable 
if studies were to be limited to participants not previously 
exposed to methylphenidate. This would allow potential side 
effects to be evaluated with regard to both frequency and 
severity. Future studies should set out to study changes in 
behavior or at the very least side effects in general. The use 
of assessment tools would improve comparability between 
studies by allowing side effects to be both recorded and 
evaluated. Funding by pharmaceutical companies should 
always be treated with caution.
The question of whether methylphenidate treatment 
is associated with behavioral effects remains to be fully 
elucidated. What is clear, however, is that children and ado-
lescents continue to be treated with substances regulated by 
the Narcotics Drug Act, and that they are often exposed to 
these drugs for many years, and at a time when their brains 
are still growing and therefore vulnerable. The fact that the 
long-term safety of these drugs remains to be fully eluci-
dated means that there is an urgent need for further research. 
In April 2016, Inglis et al published the study protocol of 
the ADDUCE study, a prospective observational study to 
investigate long-term adverse effects of methylphenidate 
in children and adolescents with ADHD, funded by the 
European Commission. Hopefully, this study can offer some 
security for the further use of methylphenidate.67
Summary and conclusion
In Germany, the use of methylphenidate is regulated by 
the Narcotic Drugs Act (Betäubungsmittelgesetz). Among 
other disorders, methylphenidate is used in the treatment of 
children and adolescents with ADHD. Since 2011, the drug 
has been licensed for use in adults with ADHD.
The fact that methylphenidate is often used over many 
years raises the following questions. Does methylphenidate 
lead to changes in behavior either during or after treatment? 
At what point do changes in behavior occur? Has there been 
sufficient research into the side effects of treatment with 
methylphenidate, and does this research include the period 
after treatment is discontinued?
An analysis of the articles included in the list of references 
provides the following answers. Seven studies specifically set 
out to study, record, and discuss changes in behavior.31,40–42, 
59,63,64 Eight studies did not set out to study behavioral effects, 
but recorded and discussed them.16,32,45,46,48,50,52,61 A total of 28 
studies recorded behavioral effects, but failed to discuss these 
further.14,15,17,19,21–30,32–39,44,47,49,51,53–58,60,66 Three studies did not 
include behavioral effects.18,43,62
Findings from our review of the selected studies can be 
summarized as follows. While there is some evidence to 
suggest that methylphenidate causes changes in behavior, 
the majority of the studies reviewed paid little or no attention 
to this issue. Based on the available data, it is impossible to 
determine the point at which such behavioral effects occur. 
The frequency of occurrence of behavioral effects is also 
impossible to determine with certainty. Based on the available 
data, it is not possible to rule out whether behavioral effects 
may persist or not persist once treatment is discontinued.
There is a relative dearth of studies dealing with the 
long-term outcomes of methylphenidate treatment and the 
issue of posttreatment follow-up. As a result, this literature 
review was unable to establish a good safety profile for 
the drug. Further studies are needed, which in order to 
provide meaningful data will need to meet certain quality 
criteria. Aside from being randomized, placebo-controlled, 
and double-blind multicenter studies, they will need to 
include a sufficient number of participants. They will also 
need to be of sufficient duration to allow conclusions regard-
ing the long-term effects of methylphenidate. Participants 
should be methylphenidate-naïve. A follow-up phase must 
be included if the reversibility of behavioral effects is to be 
studied. In conclusion, despite countless publications and 
extensive administration, especially to children, we have 
insufficient data to judge the long-term effects and risks of 
taking methylphenidate.
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